Since 1967, the lives of countless babies have been saved by the pioneering Rh Program - and to date, over three million doses of anti-D have been given to Rh negative women.
The program provides plasma collected from blood donors with anti-D for production of anti-D immunoglobulin for treatment of RhD negative women with babies at risk of haemolytic disease of the fetus and newborn (HDFN).
We're celebrating this 50-year milestone with two presentations commemorating the program and looking at the prevention of Rh HDFN - and you can find these presentations along with a back catalogue of all of our webinars at Transfusion Online Learning.
The Blood Service has recently published the results of our recently completed hepatitis E virus (HEV) RNA prevalence study. HEV is a known transfusion-transmissible agent.
Blood Service in Brief July Edition is here! We're celebrating 50 years of anti-D, preparing for the ISBT 128 Transition Label, helping health professionals with new audit tools and more.
The Information Standard for Blood and Transplant (ISBT) 128 is a global standard for the identification, labelling and information transfer of medical products of human origin.
The National Blood Authority (NBA) has directed the Blood Service to move to this standard in order to meet international benchmarking standards for product identification.